Australia: ANL Starts Phase I Trial
ANL begins Phase I trial of AN4035
Story updates
11:46:14 AM UTC
SquawkNews
ANL Adlai Nortye announces clinical trial notification submission and hrec approval for the phase I clinical trial of pan-ras(on) inhibitor Adc an4035 in Australia Adlai Nortye - in process of ind submissions for an4035 to U.S. FDA and China nmpa
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.